Medical - Diagnostics & Research
Compare Stocks
5 / 10Stock Comparison
CHEK vs ISRG vs SYK vs MDT vs ZBH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Devices
CHEK vs ISRG vs SYK vs MDT vs ZBH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $12M | $161.07B | $112.69B | $99.94B | $16.32B |
| Revenue (TTM) | $0.00 | $10.58B | $25.12B | $35.48B | $8.41B |
| Net Income (TTM) | $-25M | $2.98B | $3.25B | $4.61B | $761M |
| Gross Margin | — | 66.3% | 63.5% | 61.9% | 70.0% |
| Operating Margin | — | 30.5% | 22.4% | 17.9% | 15.6% |
| Forward P/E | — | 43.8x | 19.6x | 14.1x | 9.8x |
| Total Debt | $136K | $303M | $14.86B | $28.52B | $7.52B |
| Cash & Equiv. | — | $3.37B | $4.01B | $2.22B | $592M |
CHEK vs ISRG vs SYK vs MDT vs ZBH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Jan 26 | Return |
|---|---|---|---|
| Check-Cap Ltd. (CHEK) | 100 | 19.8 | -80.2% |
| Intuitive Surgical,… (ISRG) | 100 | 292.9 | +192.9% |
| Stryker Corporation (SYK) | 100 | 179.6 | +79.6% |
| Medtronic plc (MDT) | 100 | 97.4 | -2.6% |
| Zimmer Biomet Holdi… (ZBH) | 100 | 73.4 | -26.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHEK vs ISRG vs SYK vs MDT vs ZBH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CHEK is the #2 pick in this set and the best alternative if quality and momentum is your priority.
- 212.2% margin vs ZBH's 9.1%
- +112.2% vs SYK's -22.5%
ISRG ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
- 5.5% 10Y total return vs SYK's 187.1%
- 20.5% revenue growth vs CHEK's -48.5%
SYK is the clearest fit if your priority is valuation efficiency.
- PEG 1.32 vs MDT's 36.00
MDT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Lower volatility, beta 0.47, Low D/E 59.1%, current ratio 1.85x
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Beta 0.47 vs ISRG's 1.02
ZBH is the clearest fit if your priority is value.
- Lower P/E (9.8x vs 14.1x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs CHEK's -48.5% | |
| Value | Lower P/E (9.8x vs 14.1x) | |
| Quality / Margins | 212.2% margin vs ZBH's 9.1% | |
| Stability / Safety | Beta 0.47 vs ISRG's 1.02 | |
| Dividends | 3.6% yield, 36-year raise streak, vs SYK's 1.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +112.2% vs SYK's -22.5% | |
| Efficiency (ROA) | 175.8% ROA vs CHEK's -66.7%, ROIC 6.0% vs -287.7% |
CHEK vs ISRG vs SYK vs MDT vs ZBH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CHEK vs ISRG vs SYK vs MDT vs ZBH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
ZBH leads 1 • MDT leads 1 • CHEK leads 0 • SYK leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT and CHEK operate at a comparable scale, with $35.5B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ZBH's 9.1%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $10.6B | $25.1B | $35.5B | $8.4B |
| EBITDAEarnings before interest/tax | -$26M | $3.8B | $6.3B | $9.4B | $2.3B |
| Net IncomeAfter-tax profit | -$25M | $3.0B | $3.2B | $4.6B | $761M |
| Free Cash FlowCash after capex | -$8,004 | $2.8B | $4.3B | $5.4B | $1.8B |
| Gross MarginGross profit ÷ Revenue | — | +66.3% | +63.5% | +61.9% | +70.0% |
| Operating MarginEBIT ÷ Revenue | — | +30.5% | +22.4% | +17.9% | +15.6% |
| Net MarginNet income ÷ Revenue | — | +28.2% | +12.9% | +13.0% | +9.1% |
| FCF MarginFCF ÷ Revenue | — | +26.8% | +17.1% | +15.2% | +21.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +23.0% | +11.4% | +8.8% | +9.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -155.6% | +18.8% | +56.0% | -11.9% | +34.1% |
Valuation Metrics
ZBH leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12M | $161.1B | $112.7B | $99.9B | $16.3B |
| Enterprise ValueMkt cap + debt − cash | $12M | $158.0B | $123.5B | $126.2B | $23.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.48x | 57.62x | 35.03x | 21.60x | 23.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 43.84x | 19.62x | 14.13x | 9.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x | 2.36x | 36.00x | — |
| EV / EBITDAEnterprise value multiple | — | 43.62x | 20.31x | 14.32x | 9.47x |
| Price / SalesMarket cap ÷ Revenue | — | 16.00x | 4.49x | 2.98x | 1.98x |
| Price / BookPrice ÷ Book value/share | — | 9.17x | 5.02x | 2.08x | 1.30x |
| Price / FCFMarket cap ÷ FCF | — | 64.67x | 26.31x | 19.28x | 11.09x |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-2 for CHEK. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SYK's 0.66x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs CHEK's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.3% | +16.9% | +15.0% | +9.4% | +5.8% |
| ROA (TTM)Return on assets | -66.7% | +14.8% | +6.9% | +175.8% | +3.3% |
| ROICReturn on invested capital | -2.9% | +15.0% | +11.4% | +6.0% | +5.4% |
| ROCEReturn on capital employed | -2.3% | +16.5% | +13.0% | +7.5% | +6.9% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | — | 0.02x | 0.66x | 0.59x | 0.59x |
| Net DebtTotal debt minus cash | $136,000 | -$3.1B | $10.8B | $26.3B | $6.9B |
| Cash & Equiv.Liquid assets | — | $3.4B | $4.0B | $2.2B | $592M |
| Total DebtShort + long-term debt | $136,000 | $303M | $14.9B | $28.5B | $7.5B |
| Interest CoverageEBIT ÷ Interest expense | -2883.22x | — | 6.72x | 9.08x | 4.08x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $703 for CHEK. Over the past 12 months, CHEK leads with a +112.2% total return vs SYK's -22.5%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs ZBH's -14.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +21.3% | -19.3% | -15.2% | -18.1% | -7.1% |
| 1-Year ReturnPast 12 months | +112.2% | -15.4% | -22.5% | -2.8% | -10.4% |
| 3-Year ReturnCumulative with dividends | +48.6% | +49.6% | +5.5% | -4.2% | -37.2% |
| 5-Year ReturnCumulative with dividends | -93.0% | +58.7% | +21.5% | -27.7% | -47.3% |
| 10-Year ReturnCumulative with dividends | -99.7% | +554.2% | +187.1% | +26.5% | -17.8% |
| CAGR (3Y)Annualised 3-year return | +14.1% | +14.4% | +1.8% | -1.4% | -14.4% |
Risk & Volatility
Evenly matched — MDT and ZBH each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than ISRG's 1.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ZBH currently trades 77.0% from its 52-week high vs CHEK's 53.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.67x | 1.02x | 0.55x | 0.47x | 0.65x |
| 52-Week HighHighest price in past year | $3.92 | $603.88 | $404.87 | $106.33 | $108.29 |
| 52-Week LowLowest price in past year | $0.59 | $427.84 | $289.91 | $77.16 | $79.83 |
| % of 52W HighCurrent price vs 52-week peak | +53.1% | +75.1% | +72.7% | +73.3% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 58.5 | 42.4 | 24.3 | 27.3 | 34.3 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 1.8M | 2.1M | 7.8M | 2.2M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ISRG as "Buy", SYK as "Buy", MDT as "Buy", ZBH as "Hold". Consensus price targets imply 40.5% upside for MDT (target: $110) vs 17.4% for ZBH (target: $98). For income investors, MDT offers the higher dividend yield at 3.57% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $622.60 | $403.69 | $109.50 | $97.90 |
| # AnalystsCovering analysts | — | 55 | 50 | 49 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | — | +1.1% | +3.6% | +1.1% |
| Dividend StreakConsecutive years of raises | — | — | 34 | 36 | 0 |
| Dividend / ShareAnnual DPS | — | — | $3.36 | $2.78 | $0.96 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | +3.2% | +3.0% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ZBH leads in 1 (Valuation Metrics). 1 tied.
CHEK vs ISRG vs SYK vs MDT vs ZBH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CHEK or ISRG or SYK or MDT or ZBH a better buy right now?
For growth investors, Intuitive Surgical, Inc.
(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Intuitive Surgical, Inc. (ISRG) a "Buy" — based on 55 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHEK or ISRG or SYK or MDT or ZBH?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — CHEK or ISRG or SYK or MDT or ZBH?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -93. 0% for Check-Cap Ltd. (CHEK). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus CHEK's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHEK or ISRG or SYK or MDT or ZBH?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus Intuitive Surgical, Inc. 's 1. 02β — meaning ISRG is approximately 119% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CHEK or ISRG or SYK or MDT or ZBH?
By revenue growth (latest reported year), Intuitive Surgical, Inc.
(ISRG) is pulling ahead at 20. 5% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -43. 3% for Check-Cap Ltd.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CHEK or ISRG or SYK or MDT or ZBH?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus 0. 0% for Check-Cap Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus 0. 0% for CHEK. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CHEK or ISRG or SYK or MDT or ZBH more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 8x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 34. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 40. 5% to $109. 50.
08Which pays a better dividend — CHEK or ISRG or SYK or MDT or ZBH?
In this comparison, MDT (3.
6% yield), ZBH (1. 1% yield), SYK (1. 1% yield) pay a dividend. CHEK, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is CHEK or ISRG or SYK or MDT or ZBH better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, CHEK: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CHEK and ISRG and SYK and MDT and ZBH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHEK is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; SYK is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; ZBH is a mid-cap quality compounder stock. SYK, MDT, ZBH pay a dividend while CHEK, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.